Neprilysin inhibition in heart failure with reduced ejection fraction: A clinical review

Pharmacotherapy

Volumn 35, Issue 9, 2015, Pages 823-837

  King, Jordan B ^a   Bress, Adam P ^a,b   Reese, Austin D ^a   Munger, Mark A ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

heart failure with reduced ejection fraction; neprilysin inhibition; pharmacotherapy; systolic heart failure; therapeutic review

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDOXATRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENKEPHALINASE INHIBITOR; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; METFORMIN; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; NESIRITIDE; OMAPATRILAT; OMEPRAZOLE; PLACEBO; SACUBITRIL PLUS VALSARTAN; VALSARTAN; WARFARIN; AMINOBUTYRIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE;

ACUTE HEART FAILURE; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DRUG DESIGN;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CHRONIC DISEASE; DRUG DESIGN; HEART FAILURE; HUMANS; NEPRILYSIN; TETRAZOLES;

EID: 84942514266     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1629     Document Type: Article

References (80)

1. U.S. Department of Health and Human Services. The booming dynamics of aging: from awareness to action. The White House Conference on Aging. Washington, DC: U.S. Department of Health and Human Services; 2011.
2. Mozaffarian D, Roger VL, Go AS, et al., Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015; 131 (4): e29-322.
3. National Center for Health Statistics. Mortality Multiple Cause Micro-data Files, 2011. Public-use data file and documentation. NHLBI tabulations. Available from http://www.cdc.gov/nchs/data-access/Vitalstatsonline.htm#MortalityMultiple. Accessed July 3, 2014.
4. Roger VL, Weston SA, Redfield MM, et al., Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292 (3): 344-50.
5. Cohn JN, Tognoni G,; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667-75.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23): 1429-35.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293-302.
8. Young JB, Dunlap ME, Pfeffer MA, et al., Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110 (17): 2618-26.
9. Cohn JN, Fowler MB, Bristow MR, et al., Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997; 3 (3): 173-9.
10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001-7.
11. Packer M, Bristow MR, Cohn JN, et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334 (21): 1349-55.
12. Pitt B, Zannad F, Remme WJ, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-17.
13. Zannad F, McMurray JJ, Krum H, et al., Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11-21.
14. Levy D, Kenchaiah S, Larson MG, et al., Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347 (18): 1397-402.
15. McMurray JJ, Packer M, Desai AS, et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371 (11): 993-1004.
16. Katz AM,. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994; 121 (5): 363-71.
17. Vardeny O, Miller R, Solomon SD,. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fails 2014; 2 (6): 663-70.
18. Parker RB, Nappi JM, Cavallari LH,. Chronic Heart Failure. In:, DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 9th ed. New York, NY: McGraw-Hill, 2014. 85-122.
19. Correa de Sa DD, Chen HH,. The role of natriuretic peptides in heart failure. Curr Heart Fail Rep 2008; 10: 182-9.
20. Wilkins MR, Redondo J, Brown LA,. The natriuretic-peptide family. Lancet 1997; 349 (9061): 1307-10.
21. Ngo DTM, Horowitz JD, Sverdlov AL, et al., Heart failure: a corin-deficient state? Hypertension 2013; 61 (2): 284-5.
22. Del Ry S, Cabiati M, Stefano T,. Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regul Pept 2011; 166 (1-3): 15-20.
23. Vardeny O, Tacheny T, Solomon SD,. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 2013; 94 (4): 445-8.
24. Potter LR,. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011; 278 (11): 1808-17.
25. Clerico A, Emdin M,. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50.
26. Yasue H, Yoshimura M, Sumida H, et al., Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994 l; 90 (1): 195-203.
27. Richards M, Nicholls MG, Yandle TG, et al., Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97 (19): 1921-9.
28. Miller WL, Phelps MA, Wood CM, et al., Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011; 4 (3): 355-60.
29. Liang F, O'Rear J, Schellenberger U, et al., Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007; 49: 1071-8.
30. Chen HH,. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!. J Am Coll Cardiol 2007; 49 (10): 1089-91.
31. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287 (12): 1531-40.
32. O'Connor CM, Starling RC, Hernandez AF, et al., Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365 (1): 32-43.
33. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K,. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293 (15): 1900-5.
34. Kerr MA, Kenny AJ,. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 1974; 137: 477-88.
35. McMurray JJ,. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail 2015; 17 (3): 242-7.
36. Erdos EG, Skidgel RA,. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3 (2): 145-51.
37. Abassi Z, Golomb E, Keiser HR,. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabolism 1992; 41 (7): 683-5.
38. Murphy LJ, Corder R, Mallet AI, Turner AJ,. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol 1994; 113 (1): 137-42.
39. O'Connell JE, Jardine AG, Davidson G, Connell JM,. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10 (3): 271-7.
40. McDowell G, Nicholls DP,. The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans. Cardiovasc Drug Rev 2000; 18 (4): 259-70.
41. Ferro CJ, Spratt JC, Haynes WG, Webb DJ,. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998; 97 (23): 2323-30.
42. Rouleau JL, Pfeffer MA, Stewart DJ, et al., Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356 (9230): 615-20.
43. Packer M, Califf RM, Konstam MA, et al., Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106 (8): 920-6.
44. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E,. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17 (2): 103-11.
45. Fryer RM, Segreti J, Banfor PN, et al., Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008; 153 (5): 947-55.
46. Gu J, Noe A, Chandra P, et al., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50 (4): 401-14.
47. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Lüscher TF,. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001; 104 (15): 1856-62.
48. Potter LR, Abbey-Hosch S, Dickey DM,. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27 (1): 47-72.
49. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M,. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21 (7): 733-41.
50. Nishikimi T, Maeda N, Matsuoka H,. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 69 (2): 318-28.
51. Kario K, Sun N, Chiang FT, et al., Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 2014; 63 (4): 698-705.
52. Steckelings UM, Paulis L, Namsolleck P, Unger T,. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 2012; 21 (2): 142-6.
53. Ayalasomayajula SP, Chandra P, Wolfson E, et al., Effect of food on the oral bioavailability of LCZ696. Poster presented at: American College of Clinical Pharmacology; August 14-16, 2014; Atlanta, GA.
54. Langenickel T, Ayalasomayajula SP, Jordaan P, Albrecht D, We. Assessment of Steady State Pharmacokinetics of LCZ696 in Patients with Renal Impairment. Poster presented at: American College of Clinical Pharmacology; August 14-16, 2014; Atlanta, GA.
55. Ayalasomayajula S, Jordaan P, Pal P, et al., Assessment of drug interaction potential between LCZ696 and warfarin. Hypertension 2013; 62: 448.
56. Solomon SD, Zile M, Pieske B, et al., The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380 (9851): 1387-95.
57. Novartis Pharmaceuticals. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01920711 NLM Identifier: NCT01920711. Accessed January 7, 2015.
58. Prasad PP, Yeh CM, Gurrieri P, Glazer R, McLeod J,. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 2002; 40 (5): 801-7.
59. McMurray JJV, Packer M, Desai AS, et al., Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15 (9): 1062-73.
60. Packer M, McMurray JJ, Desai AS, et al., Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131 (1): 54-61.
61. Gan L, Langenickel T, Kode K, et al., Age and gender effects on the pharmacokinetics of LCZ696. Poster presented at: American College of Clinical Pharmacology; August 14-16, 2014; Atlanta, GA.
62. Kulmatycki K, Langenickel T, Ng D, et al., Pharmacokinetics of Single Dose LCZ696 in Subjects with Mild and Moderate Hepatic Impairment. Poster presented at: American College of Clinical Pharmacology; August 14-16, 2014; Atlanta, GA.
63. Hsiao H, Langenickel TH, Greeley M, et al., Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clin Pharmacol Drug Dev 2015 May 6 [early online]. doi: 10.1002/cpdd.183.
64. Ayalasomayajula S, Jordaan P, Pal P, et al., Assessment of pharmacokinetic drug interaction between LCZ696 and digoxin. Hypertension 2013; 62: 449.
65. Gan L, Jiang X, Mendonza A, et al., Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clin Pharmacol Drug Dev 2015 [early online]. doi: 10.1002/cpdd.181.
66. Hsiao H-L, Greeley M, Pal P, et al., Assessment of pharmacokinetic drug-drug interaction between LCZ696 and carvedilol. Hypertension 2013; 62: 457.
67. Hsiao H-L, Greeley M, Pal P, et al., Assessment of pharmacokinetic drug-drug interaction between LCZ696 and hydrochlorothiazide. Hypertension 2013; 62: 455.
68. Mendonza A, Akahori M, Langenickel T, et al., Assessment of pharmacokinetic drug interaction between LCZ696 and metformin. Hypertension 2013; 62: 456.
69. Califf RM,. LCZ696: too good to be true? Eur Heart J 2014. pii: ehu501. [Epub ahead of print].
70. Konstam MA, Neaton JD, Dickstein K, et al., Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374 (9704): 1840-8.
71. McMurray JJ, Ostergren J, Swedberg K, et al., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362 (9386): 767-71.
72. Gibbs CR, Lip GY, Beevers DG,. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48 (6): 861-5.
73. Weber MA, Messerli FH,. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008; 51 (6): 1465-7.
74. Cohn JN, Archibald DG, Ziesche S, et al., Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314 (24): 1547-52.
75. Cohn JN, Johnson G, Ziesche S, et al., A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325 (5): 303-10.
76. Granger CB, McMurray JJ, Yusuf S, et al., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362 (9386): 772-6.
77. McMurray J, Packer M, Desai A, et al., A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 2015; 36 (7): 434-9.
78. Altman DG, Andersen PK,. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319 (7223): 1492-5.
79. Hildebrandt M, Vervolgyi E, Bender R,. Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Med Res Methodol 2009; 20 (9): 21.
80. American Heart Association Emerging Science Series. [Video], Has the PARADIGM for heart failure really changed? 2014 Oct 28; [22 min., 29 sec.]. Available from http://engage.vevent.com/index.jsp?eid=2224&seid=332. Accessed October 28, 2014.